Extracellular Matrix (ECM) Therapy in Tacoma, WA

CDC PLACES vs. JF: two files, not one brochure

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 10.9% of adults in Tacoma have diagnosed diabetes — 1.1 points below the U.S. 12% figure. 9.3% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick extracellular matrix therapy against that mix.

Cash PRP and Medicare CTPs in the same hallway

• CDC PLACES (2023, crude) estimates 10.9% of adults in Tacoma have diagnosed diabetes — 1.1 points below the U.S. 12% figure. Adult arthritis here is 25.1% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market extracellular matrix therapy in Tacoma. Mixing lanes is how recoupments start.
• PRP is autologous and not an HCT/P 361 allograft, but payers in JF still expect diagnosis-driven documentation. A 1-minute spin does not replace a medically necessary indication or a procedure note.
• Washington public-health data live at Washington State Department of Health. Use those pages for community education; use FDA tissue-bank paperwork for the product in the fridge. Mixing the two is how practices get warning letters.

Payer geography for Tacoma, WA

America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Tacoma we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 10.9% of adults in Tacoma have diagnosed diabetes — 1.1 points below the U.S. 12% figure.

Before the first extracellular matrix therapy shipment